The phase 2a trial showed GR-0621 met primary and secondary endpoints, demonstrating safety and efficacy over 12 weeks. Phase 2a data show oral GRI-0621 was safe and improved immune and fibrosis ...

The Global Alzheimer’s Platform Foundation® (GAP) is pleased to welcome Spear Bio, a biotechnology company pioneering ...

A new international study has demonstrated that Alzheimer's disease biomarkers can be accurately detected using simple finger-prick blood samples that can be collected at home and mailed to ...

Clene is scheduled to meet with the FDA in the coming months to discuss new data for CNM-Au8, its experimental oral therapy ...

In patients with cystic fibrosis, CMTX-101, an immune-enabling antibody therapy, lowered four inflammatory biomarkers and ...

Trastuzumab-based regimens were the primary treatment for older adults with advanced HER2-positive gastric cancer before immunotherapy became standard. The study highlights substantial economic ...

A study presented at ESCMID Global 2025 has uncovered the potential of interleukin-6 (IL-6) as a powerful diagnostic biomarker for the early detection of sepsis in high-risk patient groups, including ...

This study shows that specific ratios of circulating sphingolipids to steroids can predict the risk of future asthma ...

Switzerland: Researchers have found in a new study that Junctional protein associated with coronary artery disease (JCAD) has ...

*A study published in GeroScience has identified common biomarkers, such as cholesterol and glucose levels, in individuals who live past 90, commonly known as Centenarians. Using data from 44,000 ...